Zepbound is officially the most prescribed weight management medication in 2025

Eli Lilly has recently announced that the U.S. FDA has approved a label expansion for Zepbound to include the four-dose single-patient use KwikPen that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and healthcare providers can select the option that best fits individual needs, preferences, and circumstances. Patients, with a valid prescription, opting for self-pay through LillyDirect, can receive all doses of Zepbound in a KwikPen or single dose vial, starting at $299 per month for the 2.5 mg dose.

“Zepbound is the #1 prescribed injectable obesity‑management medication,³ helping adults achieve meaningful and clinically proven weight loss, on average, up to 50 pounds as seen in SURMOUNT-5,” said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. “As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines.”

“After trying so many times to lose weight over the years, I’m grateful I talked to my doctor about Zepbound,” said Jacob M., Zepbound patient and LillyDirect customer. “Along with diet and exercise, Zepbound has helped me make real, lasting progress. And LillyDirect made getting the medicine simple, from filling my prescription to home delivery. I feel supported at every step of my weight loss journey.”

Note that the demand for Zepbound highlights its strong efficacy profile. In the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo. In the SURMOUNT-5 open-label study, people who took Zepbound on average lost 50 lbs compared to people who took injectable Wegovy and on average lost 33 lbs. See additional data below.

In addition, Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound may also help adults with moderate-to-severe obstructive sleep apnea and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. However, note that it is not known whether Zepbound is safe and effective for use in children.

Individual results may vary and Zepbound is not for cosmetic weight loss. Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider.

---

---

Related Topics and Keywords

tirzepatide, Zepbound™